What JAMA's 68-Million-Patient Study Actually Reveals About Ivermectin, Fenbendazole, and Cancer (2026)
Abstract
A 2026 study published in JAMA Network Open has reignited debate over the use of ivermectin and benzimidazole drugs—including fenbendazole and mebendazole—among cancer patients. The study analyzed approximately 68.4 million patient records and documented a substantial increase in prescriptions following a widely viewed discussion on The Joe Rogan Experience featuring actor Mel Gibson.
While supporters view the publication as validation that these drugs are being increasingly used in real-world cancer settings, critics emphasize that the study evaluated prescribing behavior rather than clinical outcomes. This distinction is critical. The study did not assess tumor response, progression-free survival, overall survival, or quality-of-life outcomes.
This article examines what the study found, what it did not find, and why the publication has become a focal point in the ongoing debate surrounding drug repurposing in oncology.
Introduction
A 2026 study published in JAMA Network Open examined prescribing patterns for ivermectin and benzimidazole drugs following a highly publicized podcast appearance by Mel Gibson on the Joe Rogan Experience. Using data from approximately 68.4 million patient records, researchers observed a substantial increase in combination prescribing, particularly among cancer patients. However, the study did not evaluate whether these medications improved cancer outcomes, reduced mortality, or affected progression-free survival.
The resulting publication in JAMA Network Open has generated significant attention—not because it proved these drugs treat cancer, but because it confirmed that public discussion can substantially influence medical behavior.
What the JAMA Study Found
Researchers analyzed electronic health records from approximately 68.4 million patients.
The primary objective was to evaluate prescribing trends before and after the January 2024 Joe Rogan podcast episode featuring Mel Gibson.
Key findings included:
Prescriptions involving ivermectin and benzimidazole combinations increased substantially after the podcast.
The increase was particularly pronounced among patients with cancer diagnoses.
Prescribing growth was strongest among males, White patients, and residents of the Southern United States.
The trend persisted beyond the initial publicity period.
The study's authors concluded that high-profile media exposure appeared associated with increased prescribing of these medications.
Importantly, these findings are based on observed prescribing behavior rather than treatment effectiveness.
What the Study Did Not Show
The publication has sometimes been interpreted as evidence supporting the effectiveness of ivermectin or fenbendazoles against cancer.
However, the study did not evaluate:
Tumor shrinkage.
Progression-free survival.
Overall survival.
Cancer recurrence rates.
Quality of life.
Adverse-event rates.
Long-term outcomes.
In other words, the study documented what physicians prescribed—not whether the treatment worked.
This distinction is essential when interpreting the findings.
Understanding the Evidence Hierarchy
One reason the debate remains contentious is that different participants often focus on different levels of evidence.
Laboratory Studies
Researchers have reported that ivermectin, mebendazole, and fenbendazole may influence multiple pathways involved in cancer biology, including:
Microtubule disruption.
Wnt/β-catenin signaling.
PI3K/AKT/mTOR pathways.
Cancer stem-cell activity.
Tumor metabolism.
Immune regulation.
These findings provide biological plausibility.
However, laboratory results frequently fail to translate into clinical success.
Animal Studies
Several animal models have demonstrated anti-tumor effects from benzimidazole compounds and ivermectin.
While encouraging, animal studies remain preliminary evidence.
Many treatments that appear promising in mice ultimately fail in humans.
Case Reports and Anecdotal Evidence
The internet contains numerous reports of individuals who attribute cancer improvement to fenbendazole, ivermectin, mebendazole, or combination protocols.
Case reports can generate hypotheses but cannot establish causality.
Questions often remain unanswered:
What other treatments were used?
Were conventional therapies involved?
Would the outcome have occurred regardless?
Were there confounding factors?
Observational Studies
The JAMA publication falls into this category.
Observational studies can identify patterns and associations but generally cannot prove effectiveness.
Randomized Controlled Trials
RCTs remain the gold standard for evaluating cancer treatments.
At present, large-scale randomized cancer trials involving ivermectin, fenbendazole, or mebendazole remain limited.
This evidence gap largely explains why major oncology organizations have not incorporated these drugs into standard cancer treatment guidelines.
Why Interest in Drug Repurposing Continues to Grow
Despite limited clinical evidence, interest in repurposed drugs continues to expand.
Several factors contribute:
Lower Cost
Many repurposed drugs are inexpensive compared with modern targeted therapies and immunotherapies.
Established Safety Profiles
These medications have often been used for decades in other indications, providing extensive safety data.
Biological Plausibility
Researchers continue publishing studies describing anti-cancer mechanisms that warrant further investigation.
Patient Demand
Patients facing advanced cancers frequently explore additional options when conventional treatments offer limited benefits.
This is particularly common in cancers with poor prognoses, such as metastatic pancreatic cancer, where median survival often remains measured in months rather than years.
Why Oncologists Remain Cautious
Most oncologists do not reject drug repurposing outright.
Rather, they emphasize the need for stronger evidence.
Several concerns remain:
Lack of large randomized trials.
Uncertain optimal dosing strategies.
Potential interactions with standard therapies.
Unknown long-term outcomes.
Risk of patients abandoning evidence-based treatments.
From an evidence-based medicine perspective, enthusiasm alone is insufficient.
Clinical benefit must be demonstrated through rigorous investigation.
The Broader Significance of the Study
Perhaps the most important contribution of the JAMA study is not what it says about ivermectin or fenbendazole.
Instead, it highlights the growing influence of decentralized information channels on healthcare decision-making.
Historically, medical information flowed primarily through:
Academic journals.
Medical conferences.
Professional societies.
Institutional guidelines.
Today, podcasts, social media platforms, independent researchers, patient communities, and alternative media outlets increasingly shape public understanding of health and disease.
The study provides measurable evidence that these channels can influence prescribing behavior at a national scale.
Frequently Asked Questions
Did the JAMA study prove ivermectin treats cancer?
No. The study evaluated prescribing trends and did not measure cancer outcomes.
Did the study prove fenbendazole works against cancer?
No. Treatment effectiveness was not assessed.
Why are researchers interested in these drugs?
Laboratory and animal studies have identified multiple potential anti-cancer mechanisms that justify further investigation.
Are ivermectin, fenbendazole, or mebendazole approved cancer treatments?
No. These drugs are generally approved for parasitic infections and are not standard oncology treatments.
Could future trials change the picture?
Yes. Well-designed clinical trials could either support or refute current hypotheses regarding anti-cancer activity.
Conclusion
The JAMA Network Open study has become a flashpoint in the ongoing discussion surrounding drug repurposing and cancer care.
The publication confirmed a substantial increase in prescribing of ivermectin-benzimidazole combinations following a highly publicized podcast appearance. However, it did not determine whether these medications improve survival, shrink tumors, or alter cancer outcomes.
Supporters view the study as evidence that interest in repurposed cancer therapies is expanding. Critics emphasize that prescribing trends should not be confused with proof of efficacy.
Both perspectives point toward the same conclusion: additional high-quality clinical research is needed.
Until such evidence emerges, ivermectin, fenbendazole, and mebendazole will likely remain among the most debated drugs in contemporary oncology—occupying the uncertain territory between biological promise, anecdotal experience, and definitive clinical proof.
.png)
.png)
Comments
Post a Comment